Cited by 978BRCA gene mutations in cancerGenetic factors in colorectal cancerPARP inhibition in cancer therapy

The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.

BRCA1 and BRCA2: 1994 and beyond

Narod, Steven A., Foulkes, William D.·2004·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

The discovery of the first gene associated with hereditary breast cancer, BRCA1, was anticipated to greatly increase our understanding of both hereditary and sporadic forms of breast cancer, and to lead to therapeutic and preventive breakthroughs. Much has been learned during the past decade about the genetic epidemiology of breast cancer, the ethnic distribution and clinical consequences of BRCA1 and BRCA2 mutations, and the central role of DNA repair in breast cancer susceptibility. The ability to translate this knowledge into novel treatments, however, remains elusive.

Integrity signals

Registry

Crossref · 10.1038/nrc1431

Cites

187 of 187 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Self-citation
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Self-citation
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Self-citation
Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.
Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K., & Sekiya, T. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2766 · Cited by 3,589
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399

Show all 187 references

Sorted by citations

Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Self-citation
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
kConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492
Cells of origin in cancer
Visvader, J. E. (2011) · Nature · doi:10.1038/nature09781 · Cited by 1,524
Surface Plasmon Resonance: A Versatile Technique for Biosensor Applications
Nguyen, H. H., Park, J., Kang, S., & Kim, M. (2015) · Sensors · doi:10.3390/s150510481 · Cited by 1,372
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B. T., & Mills, G. B. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2644 · Cited by 1,372
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W. Q., Huang, C., Huber, P., Zhou, X., Li, C. L., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,147
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Rottenberg, S., Jaspers, J. E., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 975
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response
Wang, B., Matsuoka, S., Ballif, B. A., Zhang, D., Smogorzewska, A., Gygi, S. P., & Elledge, S. J. (2007) · Science · doi:10.1126/science.1139476 · Cited by 695
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 721
Recurrent gene fusions in prostate cancer
Kumar‐Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2402 · Cited by 663
Homologous recombination and its regulation
Krejčí, L., Altmannová, V., Spirek, M., & Zhao, X. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks270 · Cited by 706
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Anders, C. K., & Carey, L. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.008 · Cited by 638
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Menear, K. A., Adcock, C., Boulter, R., Cockcroft, X. F., Copsey, L., Cranston, A. N., Dillon, K. J., Drzewiecki, J., Garman, S., Gomez, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001263 · Cited by 608
Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesisPreprint
Visvader, J. E. (2009) · Genes & Development · doi:10.1101/gad.1849509 · Cited by 603
Inherited Susceptibility to Common Cancers
Foulkes, W. D. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802968 · Cited by 583
Self-citation
DNA‐damage repair; the good, the bad, and the ugly
Hakem, R. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.15 · Cited by 577
Genetic influence on human lifespan and longevity
Hjelmborg, J., Iachine, I. A., Skytthe, A., Vaupel, J. W., McGue, M. K., Koskenvuo, M. J., Kaprio, J. A., Pedersen, N. L., & Christensen, K. (2006) · Human Genetics · doi:10.1007/s00439-006-0144-y · Cited by 498
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer
Liu, X., Holstege, H. H., van der Gulden, H. M. L., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F. A., Peterse, J. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702969104 · Cited by 476
BRCA1 regulates human mammary stem/progenitor cell fate
Liu, S., Ginestier, C., Charafe‐Jauffret, E., Foco, H., Kleer, C. G., Merajver, S. D., Dontu, G., & Wicha, M. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711613105 · Cited by 465
Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer
Warner, E., Messersmith, H., Causer, P., Eisen, A., Shumak, R., & Plewes, D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00007 · Cited by 564
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage
Wang, B., & Elledge, S. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710061104 · Cited by 464
Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study
Eisen, A. F., Lubiński, J., Klijn, J. G. M., Møller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 442
Self-citation
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Moskwa, P., Buffa, F. M., Pan, Y., Panchakshari, R. A., Gottipati, P., Muschel, R. J., Beech, J. S., Kulshrestha, R., Abdelmohsen, K., Weinstock, D. M., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.12.005 · Cited by 436
BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing
Zhao, W., Steinfeld, J. B., Liang, F., Chen, X., Maranon, D. G., Jian Ma, C., Kwon, Y., Rao, T., Wang, W., Sheng, C., et al. (2017) · Nature · doi:10.1038/nature24060 · Cited by 393
Genetic Predisposition Directs Breast Cancer Phenotype by Dictating Progenitor Cell Fate
Proia, T. A., Keller, P. J., Gupta, P. B., Klebba, I., Jones, A. D., Sedic, M., Gilmore, H. L., Tung, N., Naber, S. P., Schnitt, S. J., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2010.12.007 · Cited by 393
Effects of Age on the Detection and Management of Breast Cancer
McGuire, A., Brown, J. A. L., Malone, C. M., McLaughlin, R. P., & Kerin, M. J. (2015) · Cancers · doi:10.3390/cancers7020815 · Cited by 397
Hereditary Breast Cancer: The Era of New Susceptibility Genes
Apostolou, P., & Fostira, F. (2013) · BioMed Research International · doi:10.1155/2013/747318 · Cited by 379
Epistasis and Its Implications for Personal Genetics
Moore, J. H., & Williams, S. M. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.08.006 · Cited by 356
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
Gupta, G. K., Collier, A. L., Lee, D. C., Hoefer, R. A., Zheleva, V. P., van Reesema, L. L. S., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 336
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
JONES, P. G., Altamura, S., Boueres, J. K., Ferrigno, F., Fonsi, M., Giomini, C., Lamartina, S., Monteagudo, E. S., Ontoria, J. M., Orsale, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901188v · Cited by 326
Hereditary breast cancer: new genetic developments, new therapeutic avenues
Campeau, P. M., Foulkes, W. D., & Tischkowitz, M. D. (2008) · Human Genetics · doi:10.1007/s00439-008-0529-1 · Cited by 323
Self-citation
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
Nolan, E., Vaillant, F., Branstetter, D. G., Pal, B., Giner, G., Whitehead, L. W., Lok, S. W., Mann, G. B., Rohrbach, K., Huang, L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4118 · Cited by 312
Triple‐negative breast cancer: Present challenges and new perspectives
Podo, F., Buydens, L. M. C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I. S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., et al. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.006 · Cited by 299
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair
O'Donovan, P. J., & Livingston, D. M. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq069 · Cited by 307
Breast-Cancer Stromal Cells with TP53 Mutations and Nodal Metastases
Patócs, A., Zhang, L., Xu, Y., Weber, F., Caldés, T., Mutter, G. L., Platzer, P., & Eng, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071825 · Cited by 297
Cellular functions of the BRCA tumour-suppressor proteins
Boulton, S. J. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340633 · Cited by 299
Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Sadiković, B., Al-Romaih, K. I., Squire, J. A., & Zieleńska, M. (2008) · Current Genomics · doi:10.2174/138920208785699580 · Cited by 296
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
Gorrini, C., Baniasadi, P. S., Harris, I. S., Silvester, J., Inoue, S., Snow, B., Joshi, P. A., Wakeham, A., Molyneux, S. D., Martin, B., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121337 · Cited by 289
Targeted therapy for cancer using PARP inhibitors
Lord, C. J., & Ashworth, A. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.016 · Cited by 288
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
Young, S. R., Pilarski, R., Donenberg, T. R., Shapiro, C. L., Hammond, L. S., Miller, J., Brooks, K., Cohen, S. A., Tenenholz, B., DeSai, D., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-86 · Cited by 273
Self-citation
RAD51 paralogs: Roles in DNA damage signalling, recombinational repair and tumorigenesis
Suwaki, N., Klare, K., & Tarsounas, M. (2011) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2011.07.019 · Cited by 284
Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response
Reinhardt, H. C., & Yaffe, M. B. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3640 · Cited by 269
Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects
Evers, B., & Jonkers, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209871 · Cited by 264
Identifying Cancer Stem Cells in Solid Tumors: Case Not Proven
Hill, R. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3450 · Cited by 248
TP53 Alterations Determine Clinical Subgroups and Survival of Patients With Choroid Plexus Tumors
Tabori, U. Y., Shlien, A., Baskin, B., Levitt, S. E., Ray, P. N., Alon, N., Hawkins, C. E., Bouffet, É., Pieńkowska, M., Lafay‐Cousin, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.8169 · Cited by 245
Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Du, Y., Yamaguchi, H., Wei, Y., Hsu, J. L., Wang, H.-L., Hsu, Y.-H., Lin, W.-C., Yu, W.-H., Leonard, P. G., Lee, G. R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4032 · Cited by 252
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases
Brekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233
Understanding breast cancer – The long and winding road
Lukong, K. E. (2017) · BBA Clinical · doi:10.1016/j.bbacli.2017.01.001 · Cited by 238
Breast cancer susceptibility: current knowledge and implications for genetic counselling
Ripperger, T., Gadzicki, D., Meindl, A., & Schlegelberger, B. (2008) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.212 · Cited by 221
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1
Gonzalez, M. E., Li, X., Toy, K. A., DuPrie, M. L., Ventura, A. C., Banerjee, M., Ljungman, M. E., Merajver, S. D., & Kleer, C. G. (2008) · Oncogene · doi:10.1038/onc.2008.433 · Cited by 201
Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for CancerPreprint
Tutt, A. N. J., Lord, C. J., McCabe, N., Farmer, H., Turner, N. C., Martin, N. M. B., Jackson, S. P., Smith, G. C. M., & Ashworth, A. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.012 · Cited by 198
Hereditary breast cancer
Conejero, R. A., del Prado, R. L., Berjaga, M. Z., & Vázquez, E. A. (2022) · Revisiones en cáncer · doi:10.20960/revcancer.00003 · Cited by 193
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
JONES, P. G., Wilcoxen, K., Rowley, M., & Toniatti, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5018237 · Cited by 192
Hereditary breast and ovarian cancer: review and future perspectives
Lux, M. P., Fasching, P. A., & Beckmann, M. W. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0696-7 · Cited by 187
Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule
Zhao, Q., Lan, T., Su, S., & Rao, Y. (2018) · Chemical Communications · doi:10.1039/c8cc07813k · Cited by 187
Genetic Analysis of Chromosome Pairing, Recombination, and Cell Cycle Control during First Meiotic Prophase in Mammals
Cohen, P. E., Pollack, S. E., & Pollard, J. W. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0017 · Cited by 189
BRCA1 haploinsufficiency for replication stress suppression in primary cells
Pathania, S., Bade, S., Guillou, M. L., Burke, K. A., Reed, R., Bowman-Colin, C., Su, Y., Ting, D. T., Polyák, K., Richardson, A. L., et al. (2014) · Nature Communications · doi:10.1038/ncomms6496 · Cited by 183
Hormone replacement therapy and the risk of breast cancer
Narod, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.110 · Cited by 179
Self-citation
EWS–ETS oncoproteins: The linchpins of Ewing tumors
Janknecht, R. (2005) · Gene · doi:10.1016/j.gene.2005.08.007 · Cited by 173
NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control
Wang, B., Hurov, K., Hofmann, K., & Elledge, S. J. (2009) · Genes & Development · doi:10.1101/gad.1770309 · Cited by 172
Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions
Bartz, S. R., Zhang, Z., Burchard, J., Imakura, M., Martin, M. M., Palmieri, A., Needham, R. H. V., Guo, J., Gordon, M. L., Chung, N., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01229-06 · Cited by 178
Pathology of hereditary breast cancer
van der Groep, P., van der Wall, E., & van Diest, P. J. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0010-3 · Cited by 190
Cell-to-Cell Stochastic Variation in Gene Expression Is a Complex Genetic Trait
Ansel, J., Duplus‐Bottin, H., Rodriguez-Beltran, C., Damon‐Soubeyrand, C., Nagarajan, M., Fehrmann, S., François, J., & Yvert, G. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000049 · Cited by 169
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells
Konishi, H., Mohseni, M., Tamaki, A., Garay, J. P., Croessmann, S., Karnan, S., Ota, A., Wong, H. Y., Konishi, Y., Karakas, B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110969108 · Cited by 170
Comprehensive Analysis of Missense Variations in the BRCT Domain of BRCA1 by Structural and Functional Assays
Lee, M. S., Green, R., Marsillac, S. M., Coquelle, N., Williams, R. S., Yeung, T., Foo, D., Hau, D., Hui, B., Monteiro, Á. N. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4563 · Cited by 173
Prevention and Management of Hereditary Breast Cancer
Narod, S. A., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.035 · Cited by 167
Self-citation
Identification and Application of Gene Expression Signatures Associated with Lifespan Extension
Tyshkovskiy, A., Bozaykut, P., Borodinova, A. A., Gerashchenko, M. V., Ables, G. P., Garratt, M., Khaitovich, P., Clish, C. B., Miller, R. A., & Gladyshev, V. N. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.018 · Cited by 167
BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping
Badie, S., Escandell, J. M., Bouwman, P., Carlos, A. R., Thanasoula, M., Gallardo, M. M., Suram, A., Jaco, I., Benitez, J. J., Herbig, U., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1943 · Cited by 164
What Is Known about Breast Cancer in Young Women?
Zhu, J. W., Charkhchi, P., Adekunte, S., & Akbari, M. R. (2023) · Cancers · doi:10.3390/cancers15061917 · Cited by 186
Identification of a novel truncating PALB2mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women
Foulkes, W. D., Ghadirian, P., Akbari, M. R., Hamel, N., Giroux, S., Sabbaghian, N., Darnel, A. D., Royer, R., Poll, A., Fafard, E., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1828 · Cited by 161
Self-citation
Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells
Alimbetov, D. S., Askarova, S., Umbayev, B. A., Davis, T., & Kipling, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061690 · Cited by 159
Genomic instability in breast cancer: Pathogenesis and clinical implications
Kwei, K. A., Kung, Y., Salari, K., Holcomb, I. N., & Pollack, J. R. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.001 · Cited by 157
Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
Anders, C. K., Winer, E. P., Ford, J. M., Dent, R. A., Silver, D. P., Sledge, G. W., & Carey, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0939 · Cited by 159
Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma
Tone, A. A., Begley, H., Sharma, M., Murphy, J., Rosen, B. P., Brown, T. J., & Shaw, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4959 · Cited by 153
MYC in breast tumor progression
Chen, Y., & Olopade, O. I. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.10.1689 · Cited by 163
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer
Pruthi, S., Gostout, B. S., & Lindor, N. M. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0414 · Cited by 161
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
Park, J. H., Ahn, J. H., & Kim, S. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000357 · Cited by 158
CCDC98 targets BRCA1 to DNA damage sites
Liu, Z., Wu, J., & Yu, X. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1279 · Cited by 148
A highly annotated database of genes associated with platinum resistance in cancer
Huang, D., Savage, S. R., Calinawan, A. P., Lin, C., Zhang, B., Wang, P., Starr, T. K., Birrer, M. J., & Paulovich, A. G. (2021) · Oncogene · doi:10.1038/s41388-021-02055-2 · Cited by 150
Histone Ubiquitination Associates with BRCA1-Dependent DNA Damage Response
Wu, J., Huen, M. S. Y., Lu, L., Lin, Y., Dou, Y., Ljungman, M. E., Chen, J., & Yu, X. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01302-08 · Cited by 152
The differential view of genotype–phenotype relationships
Courtier‐Orgogozo, V., Morizot, B., & Martin, A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00179 · Cited by 161
Breast cancer stem cells: implications for therapy of breast cancer
Morrison, B. J., Schmidt, C., Lakhani, S. R., Reynolds, B. A., & López, J. A. (2008) · Breast Cancer Research · doi:10.1186/bcr2111 · Cited by 140
The functional role of the novel biomarker karyopherin α 2 (KPNA2) in cancer
Christiansen, A. B., & Dyrskjøt, L. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.12.013 · Cited by 138
Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence
Sedic, M., Skibinski, A., Brown, N. E., Gallardo, M., Mulligan, P., Martínez, P., Keller, P. J., Glover, E., Richardson, A. L., Cowan, J. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8505 · Cited by 143
Genetic susceptibility for breast cancer: How many more genes to be found?
Oldenburg, R. A., Meijers-Heijboer, H. E. J., Cornelisse, C. J., & Devilee, P. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.12.004 · Cited by 138
Survival and prognostic factors in BRCA1-associated breast cancer
Brekelmans, C. T. M., Seynaeve, C., Menke-Pluymers, M., Brüggenwirth, H. T., Tilanus‐Linthorst, M. M. A., Bartels, C. C. M., Kriege, M., van Geel, A. N., Crépin, C., Blom, J., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj095 · Cited by 136
Prognosis of BRCA-associated breast cancer: a summary of evidence
Bordeleau, L., Panchal, S., & Goodwin, P. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0566-z · Cited by 135
BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis
Foulkes, W. D. (2006) · Familial Cancer · doi:10.1007/s10689-005-2832-5 · Cited by 138
Self-citation
Diagnostic guidelines for high-resolution melting curve (HRM) analysis: An interlaboratory validation ofBRCA1mutation scanning using the 96-well LightScanner™
van der Stoep, N., van Paridon, C. D. M., Janssens, T., Křenková, P., Štambergová, A., Maçek, M., Matthijs, G., & Bakker, E. (2009) · Human Mutation · doi:10.1002/humu.21004 · Cited by 135
On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations
Hamel, N., Feng, B., Foretová, L., Stoppa‐Lyonnet, D., Narod, S. A., Имянитов, Е. Н., Sinilnikova, O. M., Tihomirova, L., Lubiński, J., Gronwald, J., et al. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.203 · Cited by 135
Self-citation
Functional Analysis of the Transcription Repressor PLU-1/JARID1B
Scibetta, A. G., Santangelo, S., Coleman, J., Hall, D. M. S., Chaplin, T., Copier, J. P., Catchpole, S., Burchell, J., & Taylor-Papadimitriou, J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00274-07 · Cited by 143
Benzopyrene exposure disrupts DNA methylation and growth dynamics in breast cancer cells
Sadiković, B., & Rodenhiser, D. I. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.06.012 · Cited by 135
Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating Enzyme E2T Overexpression in Human Breast Cancer Cells
Ueki, T., Park, J.-H., Nishidate, T., Kijima, K., Hirata, K., Nakamura, Y., & Katagiri, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1809 · Cited by 133
Analysis of the DNA Substrate Specificity of the Human BACH1 HelicaseAssociated with BreastCancer
Gupta, R., Sharma, S., Sommers, J. A., Jin, Z., Cantor, S. B., & Brosh, R. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501995200 · Cited by 131
The CRM1 nuclear export protein in normal development and disease.
Nguyen, K. T., Holloway, M. P., & Altura, R. A. (2012) · Europe PMC (PubMed Central) · Cited by 131
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions
Carcangiu, M. L., Peissel, B., Pasini, B., Spatti, G., Radice, P., & Manoukian, S. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000202161.80739.ac · Cited by 131
Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1
Neubauer, H. J., Clare, S. E., Woźny, W., Schwall, G., Poznanović, S., Stegmann, W., Vogel, U. F., Sotlar, K., Wallwiener, D. R., Kurek, R., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2155 · Cited by 131

Authors: Narod, S. A., & Foulkes, W. D.
Affiliations: Sunnybrook Health Science Centre (CA)
McGill University (CA)
Corresponding author: Narod, Steven A.
ORCID: Narod, Steven A.
Foulkes, William D.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2004-09
Volume: 4
Issue: 9
Pages: 665-676
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc1431
OpenAlex: W2091961739
Cited by: 967
References: 187
Citations by year: 2026: 13 · 2025: 29 · 2024: 30 · 2023: 37 · 2022: 36 · 2021: 40 · 2020: 30 · 2019: 31 · 2018: 33 · 2017: 35 · 2016: 38 · 2015: 53 · 2014: 38 · 2013: 43 · 2012: 59
FWCI: 6.57
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords: BRCA1, BRCA2, hereditary breast cancer, genetic susceptibility, DNA repair, genetic epidemiology, breast cancer prevention, breast cancer treatment
MeSH terms: Breast Neoplasms, DNA Damage, DNA Repair, Female, Humans, Mutation, Molecular Epidemiology, Genes, BRCA1, Genetic Predisposition to Disease, Genes, BRCA2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

BRCA1 and BRCA2: 1994 and beyond

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks